Future therapies for cystic fibrosis.
Ontology highlight
ABSTRACT: We are currently witnessing transformative change for people with cystic fibrosis with the introduction of small molecule, mutation-specific drugs capable of restoring function of the defective protein, cystic fibrosis transmembrane conductance regulator (CFTR). However, despite being a single gene disorder, there are multiple cystic fibrosis-causing genetic variants; mutation-specific drugs are not suitable for all genetic variants and also do not correct all the multisystem clinical manifestations of the disease. For many, there will remain a need for improved treatments. Those patients with gene variants responsive to CFTR modulators may have found these therapies to be transformational; research is now focusing on safely reducing the burden of symptom-directed treatment. However, modul
SUBMITTER: Allen L
PROVIDER: S-EPMC9907205 | biostudies-literature | 2023 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA